SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA.
Conference Presentation Details:
| Date: | Tuesday, January 10, 2023 | |
| Time: | 10:00 a.m. PST | |
| Location: | Track Yosemite - C (Ballroom Level) | |
| Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102 | ||
| Webcast: | LINK |
The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com.
The Company also will be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco on January 9-11, 2023. To schedule a meeting with Aptose, investors can request a meeting on the online system here.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (formerly HM43239), an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.
For further information, please contact:
| Aptose Biosciences Inc. | LifeSci Advisors, LLC | |
| Susan Pietropaolo | Dan Ferry, Managing Director | |
| Investor Relations | 617-535-7746 | |
| 201-923-2049 | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$0.21 |
| Daily Change: | 0.0009 0.44 |
| Daily Volume: | 336,073 |
| Market Cap: | US$12.460M |
January 09, 2025 December 09, 2024 December 03, 2024 November 25, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
